SEC Comment Letter for Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196) (CANF) — Jun 28, 2013
Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196)
Date: June 28, 2013 · CIK: 0001536196 · Accession: 0000000000-13-035376
AI Filing Summary & Sentiment
Reasoning
Letter
June 27, 2013 Via E -mail Pnina Fishman Chief Executive Officer Can-Fite BioPharma Ltd. 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petah -Tikva 49170, Israel
Re: Can-Fite BioPharma Ltd. Amendment No. 2 to Draft Registration Statement on Form 20 -F Filed June 14, 2013 CIK No. 0001536196
Dear Dr. Fishman:
We have reviewed your amended registration statement and correspondence dated June 14, 2013, and have the following comment.
Please respond to this letter within 10 business days by providing the requested infor mation or by advising us when you will pro vide the requested response. If you do not believe our comment applies to your facts and circu mstances, please tell us why in your response.
After revie wing the infor mation you provide in response to this comment, we may have additio nal co mments.
Pre-Clinical Studies of CF102, page 51
1. We note your response to our prior comment 21 and reissue the comment in part. Please expand your disclosure on page 51 to indicate whether any adverse events were experienced by patients in the second round of Phase II clinic al studies of CF102.
We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes all information the Securities Exchange Act of 1934 and all applicable Exchange Act rules r equire. Since the company and its management are in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.
In responding to our comment , please provide a written statement from the company acknowledging that:
Pnina Fishman Can-Fite BioPharma Ltd. June 27 , 2013 Page 2
the company is responsible for the adequacy and accuracy of the disclosure in the filing;
staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
the company may not assert staff comments as a defense in any proceeding initiated by the Commiss ion or any person under the federal securities laws of the United States.
Please contact Austin Stephenson at (202) 551 -3192, Bryan Pitko at (202) 551 -3203, or me at (202) 551 -3715 with any questions.
Sincerely,
/s/ Bryan J. Pitko for
Show Raw Text
June 27, 2013 Via E -mail Pnina Fishman Chief Executive Officer Can-Fite BioPharma Ltd. 10 Bareket Street Kiryat Matalon, P.O. Box 7537 Petah -Tikva 49170, Israel Re: Can-Fite BioPharma Ltd. Amendment No. 2 to Draft Registration Statement on Form 20 -F Filed June 14, 2013 CIK No. 0001536196 Dear Dr. Fishman: We have reviewed your amended registration statement and correspondence dated June 14, 2013, and have the following comment. Please respond to this letter within 10 business days by providing the requested infor mation or by advising us when you will pro vide the requested response. If you do not believe our comment applies to your facts and circu mstances, please tell us why in your response. After revie wing the infor mation you provide in response to this comment, we may have additio nal co mments. Pre-Clinical Studies of CF102, page 51 1. We note your response to our prior comment 21 and reissue the comment in part. Please expand your disclosure on page 51 to indicate whether any adverse events were experienced by patients in the second round of Phase II clinic al studies of CF102. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes all information the Securities Exchange Act of 1934 and all applicable Exchange Act rules r equire. Since the company and its management are in possession of all facts relating to a company’s disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made. In responding to our comment , please provide a written statement from the company acknowledging that: Pnina Fishman Can-Fite BioPharma Ltd. June 27 , 2013 Page 2 the company is responsible for the adequacy and accuracy of the disclosure in the filing; staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and the company may not assert staff comments as a defense in any proceeding initiated by the Commiss ion or any person under the federal securities laws of the United States. Please contact Austin Stephenson at (202) 551 -3192, Bryan Pitko at (202) 551 -3203, or me at (202) 551 -3715 with any questions. Sincerely, /s/ Bryan J. Pitko for Jeffrey P. Riedler Assistant Director cc: Via E -mail Robert L. Grossman, Esq. Greenberg Traurig, P.A.